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A B S T R A C TObjectives: To systematically review the evidence on the impact of
interventions to improve medication adherence in adults prescribed
antihypertensive medications. Methods: An electronic search was
undertaken of articles published between 1979 and 2009, without
language restriction, that focused on interventions to improve anti-
hypertensive medication adherence among patients (≥18 years) with
essential hypertension. Studies must have measured adherence as an
outcome of the intervention. We followed standard guidelines for the
conduct and reporting of the review and conducted a narrative
synthesis of reported data. Results: Ninety-seven articles were iden-
tiﬁed for inclusion; 35 (35 of 97, 36.1%) examined interventions to
directly improve medication adherence, and the majority (58 of 97,
59.8%) were randomized controlled trials. Thirty-four (34 of 97, 35.1%)see front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.03.1631
wadry-sridhar@lhsc.on.ca.
ndence to: Femida H. Gwadry-Sridhar, 268 Grosvenstudies reported a statistically signiﬁcant improvement in medication
adherence. Discussion/Conclusions: Interventions aimed at improv-
ing patients’ knowledge of medications possess the greatest potential
clinical value in improving adherence with antihypertensive therapy.
However, we identiﬁed several limitations of these studies, and advise
future researchers to focus on using validated adherence measures,
well-designed randomized controlled trials with relevant adherence
and clinical outcomes, and guidelines on the appropriate design and
analysis of adherence research.
Keywords: hypertension, intervention, medication adherence,
uncontrolled blood pressure.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Nonadherence to medications is well established as an important
contributor to poorly controlled hypertension [1–4]. However,
despite the convenience of once-daily dosing schedules of anti-
hypertensives, the relative lack of adverse effects, and the many
interventions developed to improve medicine taking [5], adher-
ence to antihypertensives remains suboptimal, resulting in
persisting rates of uncontrolled blood pressure (BP) among hyper-
tensive patients (BP below 140/90 mmHg) [6,7]. In the United
States, only 50% of the patients have good control of their BP [8].
Poor medication adherence has been widely identiﬁed as the
main cause of failure to control hypertension [9].
A quarter of patients who are newly initiated on antihyper-
tensive therapy fail to ﬁll their ﬁrst prescription [2,3]. During the
ﬁrst year of treatment, the average patient has possession of
antihypertensive medications for only 50% of the time, and only
one patient in ﬁve has sufﬁciently high adherence during this
period to achieve the beneﬁts observed in clinical trials [10].
Consequently, suboptimal implementation of a daily-dosingregimen and a lack of adherence to antihypertensive agents
[2,3,5,11,12] constitute major barriers to reductions in cardiovas-
cular mortality [10,13]. A study by Nelson et al. [14] found that
hypertensive patients who reported forgetting to take their
medication were signiﬁcantly more likely to experience a cardi-
ovascular event or death than those who reported never forget-
ting to take their medication. In 2010, hypertension cost the
United States $93.5 billion in health care services, medications,
and missed days of work [15]; improving adherence could
represent a major source of health and economic improvement
from a societal, institutional, and employers’ perspective [16–19].
A signiﬁcant proportion of nonadherence is intentional, and
despite the existence of patient-centered behavioral theories and
models developed to understand reasons for poor adherence [20–
24], there has been limited work focusing on the doctor-patient
relationship and patient health beliefs [18]. Interventions aimed
at promoting adherence are variably effective [5], a likely con-
sequence of large intraindividual variability in the factors that
inﬂuence patients’ behavior to take their medicines. An impor-
tant criterion for any adherence-enhancing intervention is that itociety for Pharmacoeconomics and Outcomes Research (ISPOR).
or Street, Room FB-112, London, Ontario N6A4V2, Canada.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 6 3 – 8 7 1864should be tailored to address the root causes of nonadherence
[21–28].
While a Cochrane review has been previously published on
interventions aimed at improving medication adherence in
hypertension [29], it included randomized controlled trials (RCTs)
published only up to 2002, of interventions directly geared at
patients. The aims of this systematic review were to update
previous reviews on examining interventions geared toward
improving medication adherence in hypertension and to broaden
the coverage of studies and interventions to be included. This
latter aim was achieved by not restricting research designs or
specifying for whom the intervention is to be directed. Our
consideration of studies besides RCTs is aligned with the notion
that different forms of evidence should be valued, in contrast to
the traditional concept of an evidence hierarchy [30].
Deﬁnition of Adherence
For the purposes of this article, dichotomous and continuous
measures of medication adherence are deﬁned as the process by
which patients take their medications as prescribed, composed of
initiation, implementation, and discontinuation [12,31–34]. We
also draw distinction between adherence and persistence accord-
ing to Vrijens et al. [12], where persistence describes the length of
time between initiation and the last dose immediately preceding
discontinuation. This article will focus on adherence to antihy-
pertensive medication only. Although medication adherence
seems to be the more preferred term, patient compliance is
recognized as a synonym for adherence provided the term is
used to describe the process by which patients take their
medications as prescribed [35]. Medication adherence will be
operationally deﬁned as dose taking in relation to what was
prescribed [35].Methods
Authors followed the Centre for Reviews and Dissemination’s
guidance for undertaking reviews in health care, and reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [36] guidelines that have also
adopted the deﬁnitions of systematic reviews and meta-Table 1 – Search strategy using PubMed, EMBASE, EBM r
PubMed MeSH he
Patient adherence AND Dise
Patient adherence Hyperte
OR Medication adherence
OR Treatment refusal
OR Patient dropout
OR
OR
OR
EMBASE, EBM reviews, and M
Patient adherence AND Dise
Adherence Hyperte
OR Persistence
OR
OR
 The wildcard character.analysis used by the COCHRANE collaboration [37]. Owing to
the diverse nature of interventions and study designs considered,
a meta-analysis (quantitative synthesis) was not conducted.
Literature Search
A literature search of articles published between January 1979
(when the ﬁrst article on adherence research was published) and
February 2009 was conducted using four electronic databases:
CINAHL, EMBASE, all EBM reviews, and MEDLINE. Databases were
selected on the basis of relevancy to the subject area (i.e.,
medicine and health) and available publication type (i.e., journal
articles). The search strategy focused on four key elements: study
design (e.g., RCTs, comparison study), sample (e.g., age of study
population), measurements of adherence and BP (self-reporting,
medication event monitoring systems), and ﬁndings (e.g.,
improvement in clinical outcomes). Search terms were deter-
mined by the research team’s own expertise and by examining
previous literature in the area. These were reﬁned iteratively on
the basis of a sample of articles identiﬁed previously as being
suitable for inclusion (Table 1).
Relevant citations and abstracts were examined independently
by eight reviewers (E.M., M.G., L.L., M.S., C.H., F.G.S., A.R.L., and
S.G.). Studies were examined to determine whether the
adherence-enhancing intervention 1) directly improved medica-
tion adherence, 2) indirectly improved medication adherence via
the involvement of a single health care provider or a multi-
disciplinary team, or 3) indirectly improved adherence through
an intervention directed at the health care provider of the multi-
disciplinary team. Interventions could constitute a number of
different approaches, including behavioral change techniques,
case management, counseling, disease management, family ther-
apy, patient education, or reminders for patients or for health
professionals.
Reviewers also hand-searched references found in included
publications for additional articles of relevance. Any duplicate and
redundant articles were ﬂagged and eliminated from the review.
Study inclusion criteria
Studies that focused on interventions to improve medication
adherence to antihypertensives in adult (≥18 years) patients witheviews, and MEDLINE.
ading search strategy
ase AND Intervention
nsion Case management
Counseling
Disease management
Health promotion
Family therapy
Patient education
Reminder system
EDLINE keyword search strategy
ase AND Intervention
nsion Behavior
Behavior
Communication
Intervention
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considered with no language restrictions. Studies were included
if 1) the intervention was adequately described, 2) the interven-
tion aimed to improve adherence to hypertension medication, 3)
adherence was measured as an outcome of the intervention, and
4) the study reported on how the measurement was achieved.
Study exclusion criteria
Studies that included the Medical Subject Headings (MeSH) terms
child and adolescent, any comment OR editorial OR letter
(publication type) were excluded. Similarly, articles that did not
deﬁne an adult (≥18 years) population or patients with secondary
hypertension were excluded from the review.
Coding and Data Management
To establish the eligibility of the study, we developed level 1, 2, and
3 data abstraction forms that ensured that relevant parameters
were available for the review. Initial screening of titles and abstracts
was performed independently and in duplicate, with a third
reviewer judging any disagreements in view. The screening forms
were developed from criteria previously used in the literature [5].
The full text of articles considered eligible for inclusion was
retrieved and subjected to level 1 review; this level addressed the
disease of interest, the year of publication, the intervention
strategy (improved adherence directly or indirectly), and the
outcomes of the study—speciﬁcally whether medication adher-
ence was reported. Independent groups of two to three reviewers
determined which abstracts met the initial screening criteria. An
article that passed the screening phase advanced to level 2
review. Level 2 abstraction involved a review of the study design
(e.g., RCT, quasi-RCT, cohort, or case-control). F.G.S. adjudicated
discrepancies between reviewer groups prior to the data extrac-
tion phase (level 3) until consensus among all groups was
reached. Data from eligible articles were extracted during level
3. These extractions related to the type of intervention used (e.g.,
behavioral, case management, counseling, disease management,Fig. 1 – Flowchart of articles throughfamily therapy, health fairs, patient education, and reminder
systems), the location of the intervention (country, clinic-based,
hospital-based, home-based), whether the intervention was
based on theory or was validated in any way, the mean adher-
ence and SD of the intervention/control group (pre or post), the
demographics of the population and sample size, the adherence
and BP measurements used, the primary outcomes, and the
statistical results of the study. We used commercial software to
facilitate the review, data extraction, and compilation (SRS 4.0,
Mobius Analytics, Ottawa, ON, Canada).Results
Identiﬁcation and Selection of Studies
The search of the databases yielded 138 citations. Of these, 41 were
rejected following the initial screening, largely because the studies
did not examine an adherence-enhancing intervention or provide
a measure of medication adherence. In total, 97 articles met the
inclusion criteria for the systematic review [38–134]. (Fig. 1)
Types of Studies and Sample Characteristics
The most common research design was RCTs including cluster
and factorial designs (58 of 97, 59.8%) [39,41,44–49,58–61,65,67–
72,76–78,81,82,84–88,90,92–94,97,98,100,104–108,110–118,121–124,
126,127,131,133] followed by cohort designs, mainly prospective
cohort studies, cross-sectional studies, and open-label designs
(13 of 97, 13.4%) [38,55,64,66,73–75,83,101,117,118,125,132], hybrid
design studies (10 of 97, 10.3%) [42,43,50,80,95,99,103,109,120,129],
systematic or literature reviews (9 of 97, 9.3%) [40,52,54,56,57,
62,79,89,120], and retrospective cohort studies (4 of 97, 4.1%)
[38,55,74,75]. Sample sizes ranged from 2 [63] to 15,519 [56], with
more than half the studies conducted in North America (United
States ¼ 51 of 97, 52.6% [38–41,44–47,49,52,54,56,57,59,62,63,67,72–
79,82,90–94,97,98,100,103,106,108,109–113,118–120,122–125,129,130];the systematic review process.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 6 3 – 8 7 1866Canada ¼ 4 of 97, 4.1% [50,51,71,89]). Study participants were
typically older (i.e.,445 years old), except one study that reported
a mean age of 39 years [63]; the highest mean age was 76.4 years
[109]. Population groups consisted of patients being treated with
antihypertensive medication for newly diagnosed or existing
grades of hypertension (with or without comorbidities). Demo-
graphics such as race (seven studies examined African-Ameri-
can/black populations) [42,46,55,94,100,116,130], location (ﬁve
studies looked at adherence levels among rural dwellers)
[43,65,85,118,128], and lifestyle habits (one study examined
adherence in hypertensive patients who consumed excessive
alcohol) [81] were also examined (see Table 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.03.1631).
Interventions, Follow-Up, and Methods of Adherence
Measurement
A variety of interventions were studied in the 97 articles (see
Table 2 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2013.03.1631). Interventions ranged from provider-
directed strategies (providers included pharmacists, physicians,
nurses, and paramedics) to multifaceted programs combining
several adherence-enhancing strategies. One study by Morisky
et al. [92] assessed a total of eight different combinations of
interventions. Methods of intervention delivery included reminder
messages, mailed packages, telephone contacts/counseling, spe
cial packaging, handouts, home visits, computer-/video-/audio-
based education programs, medication time devices, and group
and individual discussion/teaching sessions. The settings within
which interventions were delivered varied among the studies.
Interventions were most commonly delivered within a clinic
setting (32 of 97, 33.0%) [38,39,44,45,49,59–61,67,70,71,76,78,80,85,
86,90,91,96,98,103,106,107,110,119,121,125–129,132], followed by
community pharmacies (6 of 97, 6.2%) [46,48,50,51,65,66].
Follow-up to interventions occurred once or over a number of
sessions. The longest continuous study period spanned 14 years
[64], with follow-ups for interventions ranging between 2 days
[68] and 14 years [64] from baseline. Some studies did not report
baseline data on adherence and/or BP measures (30 of 97, 30.9%)
[39,43,50,66,69–71,76,80–82,87,88,90,93,94,97,101,105,108,111,112,
114,116,119,122–125,128] or follow-up times (8 of 97, 8.3%) [78,80,
82,84,101,108,119,128] (see Table 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.03.1631).
Thirty-ﬁve of 97 (35 of 97, 36.1%) [38,39,53,55,59,60,63,64,66,71–
76,83,85,87,88,91,98,101,107,111,112,114–116,118,119,122–125,130]
articles sought to improve patient medication adherence directly,
46 (46 of 97, 47.4%) [41–51,58,61,65,68–71,77,78,80,84,86,90,94–
96,99,100,102–106,108,109,113,117,121,126,127,129,131–134] sought
to improve adherence through a health care provider or multi-
disciplinary health professional process, and 4 (4 of 97, 4.1%)
[67,81,97,110] involved interventions to improve adherence indi-
rectly through changing physician or pharmacist practice. Among
interventions designed to directly improve patient adherence, 16
(16 of 35, 45.7%) [38,53,55,59,88,91,97,98,107,116,119,122–125,130]
demonstrated a statistically signiﬁcant impact on medication
adherence and 5 (5 of 35, 14.3%) [87,111,115,125,130] on BP control.
Among interventions aimed at improving adherence through a
health care provider or health care team, 15 (15 of 46, 32.6%)
[44,61,68–70,78,80,84,86,99,100,102,108,121,134] showed a statisti-
cally signiﬁcant impact on adherence and 13 (13 of 46, 28.2%)
[41,47,48,61,77,86,94,96,100,102,103,106,113] on BP control. Finally,
among interventions to improve adherence indirectly through
changing physician or pharmacist practice, 2 (2 of 4, 50.0%) [91,93]
reported statistically signiﬁcant improvements in adherence and
2 (2 of 4, 50.0%) [81,110] in BP control.
With respect to authors’ justiﬁcation for the interventions used,
20 studies (20 of 97, 20.6%) [43–45,47,50,51,59,69,71–73,77,90,109,113,115,125,129,131,132] made explicit reference to the use of a
theoretical framework to guide the research. Of these 20 studies, 6
(6 of 20, 30.0%) [45,59,69,73,115,125] demonstrated statistically sig-
niﬁcant improvements in medication adherence and 7 (7 of 20,
35.0%) [44,47,77,90,106,113,125] in BP control. A systematic review by
Ficke and Farris [62] examined the application of the transtheor-
etical model on the prescribing and use of medications—the study
found that evaluating medication taking on the basis of stage of
change can predict adherence. The most common theoretical
approaches reported were the collaborative model [43,47,77,90,
115,129], the change model [71–73], the health decision model
[44,45,59], and the PRECEDE-PROCEED model [51,59]. Other reported
models included the social ecological model [109], the nurse
managementmodel [113,132], the structural model for determinants
of adherence [125], Leventhal’s self-regulatory model of illness [131],
the cost-beneﬁt model [59], and the health belief model [69].
Measures of adherence included self-report of medication uti-
lization (46 of 97, 47.4%) [39,41,43–50,53,59,60,63,66–69,72,73,76–78,
81,82,91–94,101–104,109,114–116,125–127,130,131–134], reﬁll data or
pharmacy records (18 of 97, 18.6%) [38,50,51,70,71,74,78,90,97,
99,110,118,119,122–124,129,130], pill counts (16 of 97, 16.5%) [39,53,
64,66,68,84–86,95,96,98,105,107,111,112,116], medication event mon-
itoring systems (11 of 97, 11.3%) [58,80,83,87,88, 100,111–113,115,121],
and clinic visits (1 of 97, 1.0%) [116]. Sixteen studies (16 of 97, 16.5%)
[39,50,53,64,66,68,78,111,112,116,119,122–125,130] used two or more
measures of adherence; pill counts and self-reports were the most
frequent combination of measures (7 of 16, 43.8%) [39,50,53,66,
68,116,125]. Adherence self-reporting was often based on the
Morisky Scale or its modiﬁcations (11 of 97, 11.3%) [44,45,47,50,
53,76,77,91–94]. Other validated self-reporting measures were used
such as the Brief Medication Questionnaire [48] and the validated
Health Belief Model Questionnaire [49,69]. Theunissen et al. [131]
used the validated 5-question Medication Adherence Rating Scale;
however, this questionnaire is more speciﬁc to psychiatric as
opposed to hypertensive populations. Mehos et al. [90] asked
patients to ﬁll out a diary to assist with adherence though
information on adherence to writing in the diary was not reported.
A total of 19 studies did not provide information on the validity or
reliability of the self-reporting measure [43,46,63,66,68,72,73,81,82,
101–104,114,126,127,130,132,133].
The majority of articles included in the review described
nonpharmacological- based interventions (86 of 97, 88.7%) [39–62,
64–72,74,76–82,84–100,102–110,113,114,116,117,119,129,120–131,134];
only two studies described pharmacological interventions (i.e.,
change in taste of tablet and monitoring intensity of pharmaco-
therapy) [63,83]. An intervention was deemed nonpharmacolog-
ical if it involved patient or caregiver education (e.g., counseling,
pamphlets), decision aids (e.g., consultation packages), special
monitoring (e.g., vial caps, BP self-measurement), and/or moti-
vation techniques (e.g., diaries, reminders, follow-up interviews)
(see “Effectiveness of Interventions” section).
Although a recent study on adherence-enhancing interven-
tions in HIV was able to categorize interventions according to
determinants of adherence (i.e., knowledge, awareness, social
inﬂuence, attitude, self-efﬁcacy, intention formation, action con-
trol, maintenance, and facilitation) [135], the level of detail
available in the hypertension studies was insufﬁcient to provide
the same level of granularity. Because most of the studies did not
deﬁne behavioral change techniques, we were not able to further
classify the methods of adherence improvement according to the
determinant being addressed. We were, however, able to organize
the interventions on the basis of their location and primary focus.
Effectiveness of Interventions
Close to half of all articles (47 of 97, 48.5%) [38,41,44–48,53,55,
58,59,61,68,70,77,78,80,81,84,86–88,90,91,93,94,96,98,100,102,103,
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tically signiﬁcant improvement in either adherence or BP. Of
these 47 studies, 34 (34 of 47, 72.3%) [38,45,53,55,58,59,61,
68,70,78,80,84,86–88,90,91,93,94,96,98,100,102, 107,108,115,116,119,
122–125,130,133] demonstrated a statistically signiﬁcant improve-
ment in medication adherence (26 [26 of 34, 76.5%] [45,58,
59,61,68,70,78,84,86–88,90,91,93,94,98,100,107,108,115, 116,119,122–
124,133] were RCTs) and 24 (24 of 47, 51.1%) [41,44,46–48,
61,77,81,86,87,90,91,96,100,102,103,106,110,113,115, 117,125,130,
134] showed a statistically signiﬁcant improvement in systolic
and/or diastolic BP (18 [18 of 24, 75.0%] [41,44,46–48,61,
77,81,86,87,90,91,100,106,110,113,115,117] were RCTs). Of the
18 RCTs that reported improvements in BP, only 10 (10 of 18,
55.6%) [47,48,61,77,81,86,87,100,110,113] adequately reported
the level of medication adherence, and so limited conclusions
could be drawn on the effect of adherence on BP control. The
type of measures used may have also led to variations in the
intervention effectiveness. For instance, while Kirscht et al.
[78] achieved statistical signiﬁcance of pharmacy reﬁlls when
comparing the intervention to control, self-reported pharmacy
reﬁll was not signiﬁcantly different between the two groups.
Almost half of the interventions that reported statistical
signiﬁcance used self-reporting measures (22 of 47, 46.8%)
[41,44–48,53,59,68,77,78,81,91,93,94,102,103,116,125,130,133,134],
followed by prescription reﬁll measures (8 of 47, 17.0%) [38,70,90,
110,119,122–124] and pill counts (8 of 47, 17.0%) [53,84,86,96,98,107,
108,116]. A lack of baseline data across all studies may have
distorted the extent of impact of the intervention on adherence
or BP.
The majority of interventions were based on one or a combi-
nation of the following strategies: education (25 of 97, 25.8%)
[41,46,48,51,58,60,68,71,76,88,95,96,99,102,103,105,107,109,110,114,
117,120,126,127,129], tele-management (18 of 97, 18.6%) [42,44,45,
49,70,71,78,85,87,90,100,102,103,122,126–128,133], interviews/vis-
its (15 of 97, 15.5%) [61,91,94,98,102,104,106,108,113,116,125–127,
131,133], handouts/mail (14 of 97, 14.4%) [58,71,76,78,84,86,88,92,
99,100,102,114,116,122], reminders (14 of 97, 14.4%) [43,53,58,
71,78,85,86,94,100,110,116,122–124], self-monitoring (12 of 97,
12.4%)[41,49,50,58,72,78,87,90,95,100,105,117], provider-directed
strategies (11 of 97, 11.3%) [47,58,59,65,67,69,77,80,81,97,110],
packaging (10 of 97, 10.3%) [39,41,108,111,112,115,119,122–124],
support groups (7 of 97, 8.2%) [59,78,82,89,91–93], pharmacy
prescription proﬁles (5 of 97, 5.2%) [38,70,116,118,122], and diaries
(2 of 97, 2.1%) [88,90]. Twelve out of the 25 (12 of 25, 48.0%)
[41,46,48,58,68,88,96,102,103,107,110,117] education-based strat-
egies reported statistically signiﬁcant improvements in adher-
ence or BP. Out of the 18 interventions that were based on (or
incorporated) tele-management, 9 (9 of 18, 50.0%) [45,70,78,87,
90,100,102,103,122] reported statistical signiﬁcance. Finally, stat-
istically signiﬁcant improvements in either adherence or BP were
reported for interventions that were based on (or included)
interviews/visits (10 of 15, 66.7%) [61,91,94,98,103,106,108,113,
116,125], handouts/mail (9 of 14, 64.3%) [58,78,84,86,88,100,102,
116,122], reminders (11 of 14, 78.6%) [53,58,78,86,94,100,110,116,
122–124], self-monitoring (7 of 12, 58.3%) [41,58,78,87,90,100,117],
provider-directed strategies (7 of 11, 63.6%) [47,58,59,77,80,81,110],
packaging (7 of 10, 70.0%) [41,108,115,119,122–124], support groups
(5 of 7, 71.4%) [59,78,84,91,93], pharmacy prescription proﬁles (4 of
5, 80.0%) [70,116,118,122], and diaries (2 of 2, 100%) [88,90].
General trends and factors affecting adherence and BP control
were explored by some investigators. Bailey et al. [38] found
signiﬁcant improvement in medication adherence with increas-
ing age and provider visits, and reductions in multiple-dosing
regimens and medication class. Social function, energy/fatigue,
emotional well-being, and levels of glycohemoglobin were also
found to signiﬁcantly impact adherence behavior [73]. Bosworth
et al. [44] was able to increase patients’ conﬁdence withhypertension treatments leading to improved BP control; how-
ever, the reported results were not statistically signiﬁcant. One
study found a decrease in adherence with an increase in time
between intervention and follow-up, emphasizing the impor-
tance of interventions to promote sustainable behavior change
[58]. Overall, 56 of 97 (57.7%) [39,42,43,45,46,49,50,53,55,58–60,63–
74,76,78,82–85,92,95,97–99,101,104–109,112,114,116,121–124,126–129,
131–133] studies failed to show statistical improvements in BP
that could be related to improved adherence.Discussion/Conclusions
Our systematic review of the literature identiﬁed a broad range of
interventions with plausible effectiveness. Multiple approaches
for the delivery of interventions were described, in different
settings of care.
We identiﬁed that interventions aimed at improving patients’
knowledge of medications are of potential clinical value in
improving adherence with antihypertensive therapy—these
interventions included both patients and families through indi-
vidual and small-group sessions and used a variety of media
from informational pamphlets to personal communications. The
results of these studies support the notion that improving the
knowledge base and gaining an understanding of the long-term
risk of hypertension are valid approaches to improving adher-
ence. It is unclear, however, whether this improved knowledge
translates to improvement in the control of hypertension, or how
generalizable the results are to different settings of care.
Our review focused on hypertension, which is generally an
asymptomatic disease, though long-term uncontrolled BP predis-
poses individuals to greatly elevated risk of cardiovascular and
cerebrovascular morbidity and mortality. Because there are also
some questions about the impact of adherence on BP control, we
reviewed all articles to determine whether outcomes were col-
lected and whether adherence did affect BP control. The location
of the delivery of the intervention varied from mail outs, clinic-
based, home-based, and managed care. Most interventions were
delivered in a clinic (where nurses or other hypertension special-
ists delivered the intervention) or were based in a community
pharmacy setting. Generally, most interventions conducted did
not involve a multidisciplinary focus.
While other systematic reviews have looked at adherence-
enhancing interventions across multiple diseases and found no
effect [5,89,136], the present review focuses on a speciﬁc disease
area. This degree of speciﬁcity is a major asset to adherence
research because intervention effects cannot necessarily be gener-
alized across therapeutic areas. Narrowing our lens to interventions
to improve adherence to antihypertensive medication provides an
important focus, given the burden of hypertension-related con-
ditions, and scope for implementation of effective interventions.
We identiﬁed, however, several limitations in the studies that
assessed the efﬁcacy of adherence-enhancing interventions in
hypertension. First, the development of such interventions was
not guided routinely by conceptual models of the determinants of
nonadherence, and many were not validated, thereby limiting
the reproducibility of interventions that showed beneﬁt. Many
reasons for intentional (or deliberate) and nonintentional
(e.g., due to forgetfulness) nonadherence have been described
extensively [5,20–22,24–26,120,137,139,140]. Developers of
adherence-enhancing interventions need to build on this knowl-
edge about reasons for nonadherence to maximize the chances of
establishing efﬁcacy. In most cases, no information was provided
about the rationale for including different adherence components
(initiation, implementation, and discontinuation) of interventions
[12]. Moreover, the semantics associated with characterizing the
intervention was disparate. For example, a nonpharmacological
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 6 3 – 8 7 1868intervention could be conceptualized in many different ways
depending on authors’ interpretations. Second, most studies did
not adequately deﬁne or describe their interventions, making it
almost impossible to reproduce them in subsequent research.
There is a need to provide guidance on the ontologies used to
describe interventions so that ﬁndings can be reproduced by other
researchers. Third, the quantiﬁcation and measurement of med-
ication adherence were inconsistent. The measurement varied
from a qualitative measure of adherence (adherent vs. not) to a
more quantitative, continuous measure, but based on some
arbitrary threshold for adherence and nonadherence. Many stud-
ies often reported the proportion of patients who were adherent
without an actual measurement. The distinctions between the
various components of medication adherence were inadequately
described [12]. Fourth, there was a lack of studies measuring BP
control, other clinical biomarkers, and medication adherence, and,
notably, the impact of adherence on BP regulation. This clinical
deﬁciency places a limit on the potential inferences that can be
made between adherence improvement and BP control. Further-
more, as hypertension requires chronic treatment, it would be
worthwhile to evaluate the long-term effects of adherence inter-
ventions to improve BP control. Fifth, the methods for assessing
adherence are inconsistent across studies—ranging from self-
reports to electronic monitoring devices such as MEMSTM caps.
Many self-reported measures have not been previously validated,
thereby diminishing their utility. In addition, some studies exam-
ined multiple interventions, making it difﬁcult to interpret the
resulting beneﬁts (i.e., Did beneﬁts arise as a result of a single
intervention despite and within a multiintervention framework?
Or were the beneﬁts an overall result of a combined multidimen-
sional intervention?). Sixth, reporting of adherence rates and BP
was poor. Where mean adherence scores were provided for RCTs,
no information was available on the SDs, making it difﬁcult to
calculate effect size, which can be used as a comparative measure
across studies. Without the use of validated interventions that
could be replicated by others in the future, achieving consistent
and incremental beneﬁt in patients will be challenging. Finally,
dropouts and loss to follow-up in individual studies may have
affected the estimation of the treatment effect, the comparability
of the treatment groups, and the representativeness of study
samples in relation to the target population [141].
We have previously provided guidance on how to conduct
research on medication adherence by using both retrospective
and prospective designs [137,142]. To be clinically meaningful,
future research aimed at improving adherence has to clearly
deﬁne the interventions used, attempt to use a theoretical frame-
work to justify the proposed mode of action, and ﬁnally measure
both adherence and a clinical outcome by using evidence-based
guidelines or validated methods. In the absence of large well-
designed RCTs, this systematic review can serve as a valuable
guide for clinicians to explore the impact of nonpharmacological
interventions to improve adherence in the management of
hypertension and to use these data to plan future studies. What
is clear is that more well-designed studies are required to
illustrate the effect of adherence on clinical outcomes such as
BP control and cardiovascular health; these outcomes will form
the cornerstone of evidence-based guidelines [143]. Well-
designed RCTs of methods to support medication adherence are
warranted to ensure that patients fully beneﬁt from therapy.
These studies should be based on conceptual models that provide
a framework for the development of the interventions.Acknowledgments
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